Electrophysiological and arrhythmogenic effects of 5-hydroxytryptamine on human atrial cells are reduced in atrial fibrillation

Journal of Molecular and Cellular Cardiology

Volumn 42, Issue 1, 2007, Pages 54-62

  Pau, Davide ^a   Workman, Antony J ^a   Kane, Kathleen A ^b   Rankin, Andrew C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

5 HT; Action potentials; Atrial fibrillation; Isoproterenol; L type calcium current; Myocytes; Patch clamp

Indexed keywords

1 METHYL 3 INDOLECARBOXYLIC ACID [1 [2 (METHYLSULFONYLAMINO)ETHYL] 4 PIPERIDINYLMETHYL] ESTER; ANTILIPEMIC AGENT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ISOPRENALINE; NIFEDIPINE; NITRATE; SEROTONIN; SEROTONIN 4 RECEPTOR; WARFARIN;

ADULT; AGED; ARRHYTHMOGENESIS; ARTICLE; CALCIUM CURRENT; CELL ISOLATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART MUSCLE REFRACTORY PERIOD; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HEART SURGERY; HORMONE ACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATCH CLAMP; PRIORITY JOURNAL; SINUS RHYTHM;

ACTION POTENTIALS; ADRENERGIC BETA-ANTAGONISTS; AGED; ATRIAL FIBRILLATION; CALCIUM CHANNELS, L-TYPE; ELECTROPHYSIOLOGY; FEMALE; HEART; HEART ATRIA; HUMANS; ISOPROTERENOL; MALE; MIDDLE AGED; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; SEROTONIN;

EID: 33845644176     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2006.08.007     Document Type: Article

References (42)

1. Working Group on Atrial Fibrillation, The National Heart, Lung, and and Blood Institute Working Group on Atrial Fibrillation. Atrial fibrillation: current understandings and research imperatives. J. Am. Coll. Cardiol. 22 (1993) 1830-1834
2. 4 receptors mediate arrhythmias?. Trends Pharmacol. Sci. 15 (1994) 451-455
3. Yusuf S., Al Saady N., and Camm A.J. 5-Hydroxytryptamine and atrial fibrillation: how significant is this piece in the puzzle?. J. Cardiovasc. Electrophysiol. 14 (2003) 209-214
4. 4 receptors. FASEB J. 10 (1996) 1398-1407
5. 4 receptors. Trends Pharmacol. Sci. 16 (1995) 391-398
6. Kaumann A.J., Sanders L., Brown A.M., Murray K.J., and Brown M.J. A 5-hydroxytryptamine receptor in human atrium. Br. J. Pharmacol. 100 (1990) 879-885
7. 4-like receptor in human right atrium. Naunyn Schmiedebergs Arch. Pharmacol. 344 (1991) 150-159
8. 4 receptors. Mol. Pharmacol. 41 (1992) 346-351
9. Pau D., Workman A.J., Kane K.A., and Rankin A.C. Electrophysiological effects of 5-hydroxytryptamine on isolated human atrial myocytes, and the influence of chronic β-adrenoceptor blockade. Br. J. Pharmacol. 140 (2003) 1434-1441
10. 4 receptors by chronic β-blocker treatment. Circulation 92 (1995) 2526-2539
11. 4 receptors in human atrium: facilitation by chronic β-adrenoceptor blockade. Naunyn Schmiedebergs Arch. Pharmacol. 349 (1994) 331-337
12. 2+-channel, β-adrenoreceptor, and 5-hydroxytryptamine type 4 receptor mRNAs in human atrial fibrillation. Basic Res. Cardiol. 96 (2001) 82-90
13. World Medical Association, and World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Cardiovasc. Res. 35 (1997) 2-3
14. LeMessurier D.H., Schwartz C.J., and Whelan R.F. Cardiovascular effects of intravenous infusions of 5-hydroxytryptamine in man. Br. J. Pharmacol. 14 (1959) 246-250
15. Moe G.K. Evidence for reentry as a mechanism of cardiac arrhythmias. Rev. Physiol. Biochem. Pharmacol. 72 (1975) 55-81
16. 2+ currents and human atrial fibrillation. Circ. Res. 85 (1999) 428-436
17. Skasa M., Jungling E., Picht E., Schondube F., and Luckhoff A. L-type calcium currents in atrial myocytes from patients with persistent and non-persistent atrial fibrillation. Basic Res. Cardiol. 96 (2001) 151-159
18. 2+ current downregulation in chronic human atrial fibrillation is associated with increased activity of protein phosphatases. Circulation 110 (2004) 2651-2657
19. 2+ current by 5-HT in human atrial myocytes. Recept. Channels 10 (2004) 159-165
20. Zerkowski H.R., Broede A., Kunde K., Hillemann S., Schafer E., Vogelsang M., et al. Comparison of the positive inotropic effects of serotonin, histamine, angiotensin II, endothelin and isoprenaline in the isolated human right atrium. Naunyn Schmiedebergs Arch. Pharmacol. 347 (1993) 347-352
21. Jahnel U., Rupp J., Ertl R., and Nawrath H. Positive inotropic response to 5-HT in human atrial but not in ventricular heart muscle. Naunyn Schmiedebergs Arch. Pharmacol. 346 (1992) 482-485
22. i. Circ. Res. 87 (2000) 705-709
23. f in human atrial myocytes: focus on G protein-coupled receptors. J. Mol. Cell. Cardiol. 38 (2005) 453-460
24. 4 receptor isoforms in adult cardiomyocytes. J. Mol. Cell. Cardiol. 39 (2005) 335-344
25. αi/o-proteins. Mol. Pharmacol. 61 (2002) 85-96
26. 4i. Naunyn Schmiedebergs Arch. Pharmacol. 369 (2004) 616-628
27. Van Wagoner D.R. Electrophysiological remodeling in human atrial fibrillation. Pacing Clin. Electrophysiol. 26 (2003) 1572-1575
28. Schotten U., Ausma J., Stellbrink C., Sabatschus I., Vogel M., Frechen D., et al. Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation. Circulation 103 (2001) 691-698
29. Zicha S., Tsuji Y., Shiroshita-Takeshita A., and Nattel S. Beta-blockers as antiarrhythmic agents. Handb. Exp. Pharmacol. (2006) 235-266
30. Redpath C.J., Rankin A.C., Kane K.A., and Workman A.J. Anti-adrenergic effects of endothelin on human atrial action potentials are potentially anti-arrhythmic. J. Mol. Cell. Cardiol. 40 (2006) 717-724
31. Levy M.N. Role of calcium in arrhythmogenesis. Circulation 80 (1989) IV23-IV30
32. Pau D., Workman A.J., Kane K.A., and Rankin A.C. Electrophysiological effects of prucalopride, a novel enterokinetic agent, on isolated atrial myocytes from patients treated with b-adrenoceptor antagonists. J. Pharmacol. Exp. Ther. 313 (2005) 146-153
33. Bosch R.F., Zeng X., Grammer J.B., Popovic K., Mewis C., and Kuhlkamp V. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc. Res. 44 (1999) 121-131
34. Sun H., Leblanc N., and Nattel S. Mechanisms of inactivation of L-type calcium channels in human atrial myocytes. Am. J. Physiol. 272 (1997) H1625-H1635
35. Dobrev D. Electrical remodeling in atrial fibrillation. Herz. 31 (2006) 108-112
36. 1-adrenoceptor antagonist-treated human right atria. Eur. J. Pharmacol. 458 (2003) 163-170
37. Kur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation 110 (2004) 2299-2306
38. K,ACh and muscarinic receptor-mediated shortening of action potentials. Circulation 104 (2001) 2551-2557
39. Workman A.J., Kane K.A., and Rankin A.C. The contribution of ionic currents to changes in refractoriness of human atrial myocytes associated with chronic atrial fibrillation. Cardiovasc. Res. 52 (2001) 226-235
40. Van Wagoner D.R., and Nerbonne J.M. Molecular basis of electrical remodeling in atrial fibrillation. J. Mol. Cell. Cardiol. 32 (2000) 1101-1117
41. Brundel B.J.J.M., Henning R.H., Kampinga H.H., Van Gelder I.C., and Crijns H.J.G.M. Molecular mechanisms of remodeling in human atrial fibrillation. Cardiovasc. Res. 54 (2002) 315-324
42. Workman A.J., Kane K.A., Russell J.A., Norrie J., and Rankin A.C. Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: evidence of pharmacological remodelling. Cardiovasc. Res. 58 (2003) 518-525